Article Per Year (5 Year)
p-Index From 2020 - 2025
0.562
P-Index
This Author published in this journals
All Journal Journal of Food and Pharmaceutical Science Sciences of Pharmacy Journal of Food and Pharmaceutical Sciences
Balindra, Fredlina Rossa
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Nano Liposomal Curcumin as an Adjuvant: Enhancing Cisplatin Anticancer Effects in HeLa Cells Subandi, Subandi; Balindra, Fredlina Rossa; Gizta, Aura Bella; Khotimah, Husnul; Handono, Kusworini
Sciences of Pharmacy Volume 4 Issue 2
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0402347

Abstract

Cervical cancer, mainly driven by oncogenic HPV infections, remains a global health burden. Cisplatin is standard chemotherapy for advanced cases but is limited by toxicity. Nano liposomal curcumin, with improved bioavailability, may enhance cisplatin’s efficacy. This study investigated the combination’s effect on HeLa cells by analyzing Cyclin E1 and Bcl-2 expression. Nano liposomal curcumin was synthesized using thin-film hydration, yielding stable 32 nm nanoparticles. HeLa cells were divided into control and treatment groups, and varying doses of nano liposomal curcumin with cisplatin were received. Flow cytometry revealed significant reductions in Cyclin E1 (from 18.62 ± 1.45 to 5.79 ± 0.47) and Bcl-2 (from 32.56 ± 0.82 to 28.19 ± 0.30) at the highest dose (p < 0.05). Cell viability decreased to 9% with cisplatin alone and 1% with the combination. These results indicate that nano liposomal curcumin enhances cisplatin’s antiproliferative and pro-apoptotic effects, supporting its potential as an adjuvant to lower cisplatin doses while maintaining efficacy. Further research involving additional molecular markers, in vivo models, and clinical trials is needed to optimize dosing, confirm safety, and evaluate therapeutic potential.
A Synergistic Approach: Enhanced Apoptotic and Proliferative Inhibition of Cisplatin by Nanocurcumin in HeLa Cells Subandi, Subandi; Gizta, Aura Bella; Balindra, Fredlina Rossa; Handono, Kusworini; Khotimah, Husnul
Journal of Food and Pharmaceutical Sciences Vol 13, No 2 (2025): J.Food.Pharm.Sci
Publisher : Integrated Research and Testing Laboratory (LPPT) Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jfps.21389

Abstract

Cisplatin is a widely used chemotherapeutic agent for cervical cancer, but its effectiveness is often limited by cellular resistance and severe side effects. Curcumin has demonstrated potential to enhance cisplatin's anticancer effects by inducing apoptosis and inhibiting cell proliferation; however, its clinical use is constrained by poor solubility and low bioavailability. To overcome these limitations, liposomal nanocurcumin was developed. This study aimed to evaluate the synergistic effects of cisplatin and nanocurcumin on Bax and BrdU expression as markers of apoptosis and proliferation in HeLa cervical cancer cells. A true experimental post-test only design was employed with five groups: HeLa cell control (no treatment), positive control (cisplatin 5 µg/mL), and three treatment groups receiving cisplatin 2.5 µg/mL combined with nanocurcumin at 25, 50, and 100 µg/mL. Cells were incubated for 48 hours and analyzedusing flow cytometry. The combination treatment significantly increased Bax expression and reduced BrdU expression compared to cisplatin alone, with the strongest effect observed at 100 µg/mL nanocurcumin. These findings suggest that nanocurcumin may serve as a promising adjuvant to enhance the therapeutic efficacy of cisplatin by promoting apoptosis and suppressing proliferation in cervical cancer cells.
A Synergistic Approach: Enhanced Apoptotic and Proliferative Inhibition of Cisplatin by Nanocurcumin in HeLa Cells Subandi, Subandi; Gizta, Aura Bella; Balindra, Fredlina Rossa; Handono, Kusworini; Khotimah, Husnul
Journal of Food and Pharmaceutical Sciences Vol 13, No 2 (2025): J.Food.Pharm.Sci
Publisher : Integrated Research and Testing Laboratory (LPPT) Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jfps.21389

Abstract

Cisplatin is a widely used chemotherapeutic agent for cervical cancer, but its effectiveness is often limited by cellular resistance and severe side effects. Curcumin has demonstrated potential to enhance cisplatin's anticancer effects by inducing apoptosis and inhibiting cell proliferation; however, its clinical use is constrained by poor solubility and low bioavailability. To overcome these limitations, liposomal nanocurcumin was developed. This study aimed to evaluate the synergistic effects of cisplatin and nanocurcumin on Bax and BrdU expression as markers of apoptosis and proliferation in HeLa cervical cancer cells. A true experimental post-test only design was employed with five groups: HeLa cell control (no treatment), positive control (cisplatin 5 µg/mL), and three treatment groups receiving cisplatin 2.5 µg/mL combined with nanocurcumin at 25, 50, and 100 µg/mL. Cells were incubated for 48 hours and analyzedusing flow cytometry. The combination treatment significantly increased Bax expression and reduced BrdU expression compared to cisplatin alone, with the strongest effect observed at 100 µg/mL nanocurcumin. These findings suggest that nanocurcumin may serve as a promising adjuvant to enhance the therapeutic efficacy of cisplatin by promoting apoptosis and suppressing proliferation in cervical cancer cells.
Co-Authors Gizta, Aura Bella Kusworini Handono Subandi Subandi